利妥昔单抗联合化疗治疗复发或难治性CD20阳性B细胞前体急性淋巴细胞白血病患儿
Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
作者信息
Claviez Alexander, Eckert Cornelia, Seeger Karl, Schrauder André, Schrappe Martin, Henze Günter, von Stackelberg Arend
出版信息
Haematologica. 2006 Feb;91(2):272-3.
PMID:16461321
Abstract
We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
摘要
我们使用利妥昔单抗联合化疗治疗了3例复发或难治性CD20阳性B细胞前体急性淋巴细胞白血病患儿，这使微小残留病负荷降低或持续处于低阳性水平。两名患儿随后接受了异基因干细胞移植，在+399天和+332天时仍处于完全缓解状态。
Zotero 插件